- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Schick signs for $5 million credit, loses CFO
In an effort to bolster its business, digital detector developer Schick Technologies of Long Island City, NY, has signed a commitment letter with investment firm Greystone & Co. to provide Schick with a $5-million line of credit, subject to final
In an effort to bolster its business, digital detector developer Schick Technologies of Long Island City, NY, has signed a commitment letter with investment firm Greystone & Co. to provide Schick with a $5-million line of credit, subject to final agreement. Under terms of the deal, Greystone will gain rights to purchase Schick common stock and will fill two seats on the firms board of directors. Schick expects the transaction to close by early November.
On the management side, Schick announced the resignation of its CFO, George Rough, and that it has begun the search for his replacement. The company also named John Pauly to the post of chief operating officer. Pauly is president and CEO of PFCM Corp., a professional services company that provides management consulting services worldwide.
Study Reaffirms Low Risk for csPCa with Biopsy Omission After Negative Prostate MRI
December 19th 2024In a new study involving nearly 600 biopsy-naïve men, researchers found that only 4 percent of those with negative prostate MRI had clinically significant prostate cancer after three years of active monitoring.
Study Examines Impact of Deep Learning on Fast MRI Protocols for Knee Pain
December 17th 2024Ten-minute and five-minute knee MRI exams with compressed sequences facilitated by deep learning offered nearly equivalent sensitivity and specificity as an 18-minute conventional MRI knee exam, according to research presented recently at the RSNA conference.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.
